Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.

10.18632/oncotarget.198

Saved in:

Bibliographic Details
Main Authors:	Rao, B, van Leeuwen, I.M., Higgins, M., Campbel, J., Thompson, A.M., Lane, D.P., Lain, S.
Other Authors:	MEDICINE
Format:	Article
Published:	2020
Subjects:	aneugen antineoplastic agent aurora kinase dactinomycin imidazole derivative nutlin 3 piperazine derivative protein serine threonine kinase tozasertib aneuploidy article cell cycle cell proliferation cell protection cell strain HCT116 dose response drug antagonism drug effect evaluation gene inactivation genetics human neoplasm pathology physiology tumor cell line tumor suppressor gene Aneugens Aneuploidy Antineoplastic Combined Chemotherapy Protocols Cell Cycle Cell Line, Tumor Cell Proliferation Cytoprotection Dactinomycin Dose-Response Relationship, Drug Gene Knockout Techniques Genes, p53 HCT116 Cells Humans Imidazoles Neoplasms Piperazines Protein-Serine-Threonine Kinases
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/177792
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-177792
record_format	dspace
spelling	sg-nus-scholar.10635-1777922024-11-10T04:26:54Z Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Rao, B van Leeuwen, I.M. Higgins, M. Campbel, J. Thompson, A.M. Lane, D.P. Lain, S. MEDICINE aneugen antineoplastic agent aurora kinase dactinomycin imidazole derivative nutlin 3 piperazine derivative protein serine threonine kinase tozasertib aneuploidy article cell cycle cell proliferation cell protection cell strain HCT116 dose response drug antagonism drug effect evaluation gene inactivation genetics human neoplasm pathology physiology tumor cell line tumor suppressor gene Aneugens Aneuploidy Antineoplastic Combined Chemotherapy Protocols Cell Cycle Cell Line, Tumor Cell Proliferation Cytoprotection Dactinomycin Dose-Response Relationship, Drug Gene Knockout Techniques Genes, p53 HCT116 Cells Humans Imidazoles Neoplasms Piperazines Protein-Serine-Threonine Kinases 10.18632/oncotarget.198 Oncotarget 1 7 639-650 2020-10-20T03:22:11Z 2020-10-20T03:22:11Z 2010 Article Rao, B, van Leeuwen, I.M., Higgins, M., Campbel, J., Thompson, A.M., Lane, D.P., Lain, S. (2010). Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.. Oncotarget 1 (7) : 639-650. ScholarBank@NUS Repository. https://doi.org/10.18632/oncotarget.198 19492553 https://scholarbank.nus.edu.sg/handle/10635/177792 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Unpaywall 20201031
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	aneugen antineoplastic agent aurora kinase dactinomycin imidazole derivative nutlin 3 piperazine derivative protein serine threonine kinase tozasertib aneuploidy article cell cycle cell proliferation cell protection cell strain HCT116 dose response drug antagonism drug effect evaluation gene inactivation genetics human neoplasm pathology physiology tumor cell line tumor suppressor gene Aneugens Aneuploidy Antineoplastic Combined Chemotherapy Protocols Cell Cycle Cell Line, Tumor Cell Proliferation Cytoprotection Dactinomycin Dose-Response Relationship, Drug Gene Knockout Techniques Genes, p53 HCT116 Cells Humans Imidazoles Neoplasms Piperazines Protein-Serine-Threonine Kinases
spellingShingle	aneugen antineoplastic agent aurora kinase dactinomycin imidazole derivative nutlin 3 piperazine derivative protein serine threonine kinase tozasertib aneuploidy article cell cycle cell proliferation cell protection cell strain HCT116 dose response drug antagonism drug effect evaluation gene inactivation genetics human neoplasm pathology physiology tumor cell line tumor suppressor gene Aneugens Aneuploidy Antineoplastic Combined Chemotherapy Protocols Cell Cycle Cell Line, Tumor Cell Proliferation Cytoprotection Dactinomycin Dose-Response Relationship, Drug Gene Knockout Techniques Genes, p53 HCT116 Cells Humans Imidazoles Neoplasms Piperazines Protein-Serine-Threonine Kinases Rao, B van Leeuwen, I.M. Higgins, M. Campbel, J. Thompson, A.M. Lane, D.P. Lain, S. Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.
description	10.18632/oncotarget.198
author2	MEDICINE
author_facet	MEDICINE Rao, B van Leeuwen, I.M. Higgins, M. Campbel, J. Thompson, A.M. Lane, D.P. Lain, S.
format	Article
author	Rao, B van Leeuwen, I.M. Higgins, M. Campbel, J. Thompson, A.M. Lane, D.P. Lain, S.
author_sort	Rao, B
title	Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.
title_short	Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.
title_full	Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.
title_fullStr	Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.
title_full_unstemmed	Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.
title_sort	evaluation of an actinomycin d/vx-680 aurora kinase inhibitor combination in p53-based cyclotherapy.
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/177792
_version_	1821229423241723904

Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.

Similar Items